ID   SaOS-2
AC   CVCL_0548
SY   SAOS-2; Saos-2; SAOS 2; Saos 2; Saos2; SaOs2; SAOS2; Sarcoma OSteogenic-2; SaOS; SAOS
DR   BTO; BTO:0000971
DR   CLO; CLO_0008947
DR   CLO; CLO_0050140
DR   MCCL; MCC:0000449
DR   CLDB; cl4250
DR   CLDB; cl4251
DR   CLDB; cl4252
DR   CLDB; cl5281
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-7939
DR   BCRJ; 0217
DR   BioSample; SAMN01821594
DR   BioSample; SAMN01821661
DR   BioSample; SAMN03471126
DR   BioSample; SAMN10987923
DR   CCRID; 1101HUM-PUMC000025
DR   CCRID; 3101HUMTCHu114
DR   CCRID; 4201HUM-CCTCC00075
DR   Cell_Model_Passport; SIDM01084
DR   ChEMBL-Cells; CHEMBL3307737
DR   ChEMBL-Targets; CHEMBL614894
DR   CLS; 300331
DR   Cosmic; 687930
DR   Cosmic; 755311
DR   Cosmic; 897500
DR   Cosmic; 909707
DR   Cosmic; 931039
DR   Cosmic; 931912
DR   Cosmic; 1044086
DR   Cosmic; 1044269
DR   Cosmic; 1070841
DR   Cosmic; 1074395
DR   Cosmic; 1082492
DR   Cosmic; 1529898
DR   Cosmic; 1733126
DR   Cosmic; 2301582
DR   Cosmic; 2816206
DR   Cosmic-CLP; 909707
DR   DepMap; ACH-000410
DR   DSMZ; ACC-243
DR   DSMZCellDive; ACC-243
DR   ECACC; 89050205
DR   EGA; EGAS00001000978
DR   GDSC; 909707
DR   GEO; GSM170249
DR   GEO; GSM185150
DR   GEO; GSM185151
DR   GEO; GSM320830
DR   GEO; GSM827588
DR   GEO; GSM879222
DR   GEO; GSM1639703
DR   GEO; GSM1639704
DR   GEO; GSM1670401
DR   GEO; GSM1676314
DR   GEO; GSM1701648
DR   GEO; GSM1915012
DR   GEO; GSM1915013
DR   IARC_TP53; 21653
DR   ICLC; HTL01001
DR   KCB; KCB 200550YJ
DR   KCLB; 30085
DR   KCLB; 80023
DR   LiGeA; CCLE_519
DR   Lonza; 747
DR   NCBI_Iran; C453
DR   PharmacoDB; Saos2_1343_2019
DR   PRIDE; PXD016398
DR   PRIDE; PXD017130
DR   PRIDE; PXD021564
DR   PRIDE; PXD025970
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0548
DR   PubChem_Cell_line; CVCL_0548
DR   RCB; RCB0428
DR   RCB; RCB3688
DR   TKG; TKG 0469
DR   TOKU-E; 3085
DR   Wikidata; Q7420876
RX   PubMed=833871;
RX   PubMed=2233717;
RX   PubMed=2823272;
RX   PubMed=3040234;
RX   PubMed=3518877;
RX   PubMed=6935474;
RX   PubMed=7017212;
RX   PubMed=8617485;
RX   PubMed=10763916;
RX   PubMed=12645653;
RX   PubMed=15150091;
RX   PubMed=15736406;
RX   PubMed=15939397;
RX   PubMed=16888811;
RX   PubMed=17354236;
RX   PubMed=17431109;
RX   PubMed=17981215;
RX   PubMed=19787792;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=21519327;
RX   PubMed=22075555;
RX   PubMed=23671654;
RX   PubMed=24758355;
RX   PubMed=25031706;
RX   PubMed=26320182;
RX   PubMed=26351324;
RX   PubMed=27397505;
RX   PubMed=29334376;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK 771.
CC   Population: Caucasian.
CC   Doubling time: 48 hours (PubMed=16888811); 45.7 +- 3.3 hours (PubMed=10763916); 35-40 hours (CLS=300331); ~43 hours (DSMZ=ACC-243).
CC   Microsatellite instability: Stable (MSS) (PubMed=23671654; Sanger).
CC   Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (PubMed=2823272; PubMed=16888811; PubMed=19787792).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: H3K4me1 ChIP-seq epigenome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=1.32%; Native American=0.17%; East Asian, North=0.46%; East Asian, South=0.55%; South Asian=6.66%; European, North=52.25%; European, South=38.6% (PubMed=30894373).
CC   Discontinued: ATCC; CRL-7939; true.
CC   Discontinued: KCLB; 80023; probable.
CC   Derived from site: In situ; Bone; UBERON=UBERON_0002481.
ST   Source(s): ATCC; CCRID; CLS; Cosmic-CLP; DSMZ; ECACC; PubMed=11416159; PubMed=19787792; RCB; TKG
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 12,13
ST   D16S539: 12,13
ST   D18S51: 15 (CCRID; CLS; DSMZ; PubMed=11416159)
ST   D18S51: 15,22 (PubMed=19787792)
ST   D19S433: 13
ST   D21S11: 28,30
ST   D2S1338: 18
ST   D3S1358: 14,18
ST   D5S818: 12
ST   D7S820: 8,10
ST   D8S1179: 10,12
ST   FGA: 22,25
ST   Penta D: 11,12
ST   Penta E: 14,19
ST   SE33: 19,20
ST   TH01: 6,9
ST   TPOX: 8
ST   vWA: 18
DI   NCIt; C9145; Osteosarcoma
DI   ORDO; Orphanet_668; Osteosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   11Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 42
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
RX   PubMed=2233717; DOI=10.1128/mcb.10.11.5772-5781.1990;
RA   Diller L., Kassel J., Nelson C.E., Gryka M.A., Litwak G., Gebhardt M.,
RA   Bressac B., Ozturk M., Baker S.J., Vogelstein B., Friend S.H.;
RT   "p53 functions as a cell cycle control protein in osteosarcomas.";
RL   Mol. Cell. Biol. 10:5772-5781(1990).
RX   PubMed=2823272; DOI=10.1073/pnas.84.21.7716;
RA   Masuda H., Miller C., Koeffler H.P., Battifora H.A., Cline M.J.;
RT   "Rearrangement of the p53 gene in human osteogenic sarcomas.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:7716-7719(1987).
RX   PubMed=3040234;
RA   Rodan S.B., Imai Y., Thiede M.A., Wesolowski G., Thompson D.,
RA   Bar-Shavit Z., Shull S., Mann K., Rodan G.A.;
RT   "Characterization of a human osteosarcoma cell line (Saos-2) with
RT   osteoblastic properties.";
RL   Cancer Res. 47:4961-4966(1987).
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
RX   PubMed=6935474; DOI=10.1093/jnci/66.2.239;
RA   Wright W.C., Daniels W.P., Fogh J.;
RT   "Distinction of seventy-one cultured human tumor cell lines by
RT   polymorphic enzyme analysis.";
RL   J. Natl. Cancer Inst. 66:239-247(1981).
RX   PubMed=7017212; DOI=10.1093/jnci/66.6.1003;
RA   Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.;
RT   "HLA-A, B, C and DR alloantigen expression on forty-six cultured human
RT   tumor cell lines.";
RL   J. Natl. Cancer Inst. 66:1003-1012(1981).
RX   PubMed=8617485; DOI=10.1016/S0046-8177(96)90115-X;
RA   Scotlandi K., Serra M., Manara M.C., Benini S., Sarti M., Maurici D.,
RA   Lollini P.-L., Picci P., Bertoni F., Baldini N.;
RT   "Immunostaining of the p30/32MIC2 antigen and molecular detection of
RT   EWS rearrangements for the diagnosis of Ewing's sarcoma and peripheral
RT   neuroectodermal tumor.";
RL   Hum. Pathol. 27:408-416(1996).
RX   PubMed=10763916; DOI=10.1023/A:1006623001465;
RA   Jia S.-F., Worth L.L., Kleinerman E.S.;
RT   "A nude mouse model of human osteosarcoma lung metastases for
RT   evaluating new therapeutic strategies.";
RL   Clin. Exp. Metastasis 17:501-506(1999).
RX   PubMed=12645653; DOI=10.1016/S0165-4608(02)00685-4;
RA   Ozaki T., Neumann T., Wai D.H., Schaefer K.-L., van Valen F., Lindner N.,
RA   Scheel C., Bocker W., Winkelmann W., Dockhorn-Dworniczak B., Horst J.,
RA   Poremba C.;
RT   "Chromosomal alterations in osteosarcoma cell lines revealed by
RT   comparative genomic hybridization and multicolor karyotyping.";
RL   Cancer Genet. Cytogenet. 140:145-152(2003).
RX   PubMed=15150091; DOI=10.1158/0008-5472.CAN-03-0809;
RA   Schaefer K.-L., Brachwitz K., Wai D.H., Braun Y., Diallo R.,
RA   Korsching E., Eisenacher M., Voss R., van Valen F., Baer C., Selle B.,
RA   Spahn L., Liao S.-K., Lee K.A.W., Hogendoorn P.C.W., Reifenberger G.,
RA   Gabbert H.E., Poremba C.;
RT   "Expression profiling of t(12;22) positive clear cell sarcoma of soft
RT   tissue cell lines reveals characteristic up-regulation of potential
RT   new marker genes including ERBB3.";
RL   Cancer Res. 64:3395-3405(2004).
RX   PubMed=15736406;
RA   Pautke C., Schieker M., Tischer T., Kolk A., Neth P., Mutschler W.,
RA   Milz S.;
RT   "Characterization of osteosarcoma cell lines MG-63, Saos-2 and U-2 OS
RT   in comparison to human osteoblasts.";
RL   Anticancer Res. 24:3743-3748(2004).
RX   PubMed=15939397; DOI=10.1016/j.bbrc.2005.05.097;
RA   Hausser H.-J., Brenner R.E.;
RT   "Phenotypic instability of Saos-2 cells in long-term culture.";
RL   Biochem. Biophys. Res. Commun. 333:216-222(2005).
RX   PubMed=16888811; DOI=10.1002/jcb.21073;
RA   Moneo V., Serelde B.G., Fominaya J.M., Martinez-Leal J.F.,
RA   Blanco-Aparicio C., Romero L., Sanchez-Beato M., Cigudosa J.C.,
RA   Tercero J.C., Piris M.A., Jimeno J., Carnero A.;
RT   "Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged
RT   sarcoma cell lines correlates with mutated p53.";
RL   J. Cell. Biochem. 100:339-348(2007).
RX   PubMed=17354236; DOI=10.1002/ijc.22643;
RA   Muller C.R., Paulsen E.B., Noordhuis P., Pedeutour F., Saeter G.,
RA   Myklebost O.;
RT   "Potential for treatment of liposarcomas with the MDM2 antagonist
RT   Nutlin-3A.";
RL   Int. J. Cancer 121:199-205(2007).
RX   PubMed=17431109; DOI=10.1158/1535-7163.MCT-06-0729;
RA   Moneo V., Serelde B.G., Leal J.F.M., Blanco-Aparicio C.,
RA   Diaz-Uriarte R., Aracil M., Tercero J.C., Jimeno J., Carnero A.;
RT   "Levels of p27(kip1) determine Aplidin sensitivity.";
RL   Mol. Cancer Ther. 6:1310-1316(2007).
RX   PubMed=17981215; DOI=10.1016/j.cancergencyto.2007.08.003;
RA   Selvarajah S., Yoshimoto M., Maire G., Paderova J., Bayani J.,
RA   Squire J.A., Zielenska M.;
RT   "Identification of cryptic microaberrations in osteosarcoma by
RT   high-definition oligonucleotide array comparative genomic
RT   hybridization.";
RL   Cancer Genet. Cytogenet. 179:52-61(2007).
RX   PubMed=19787792; DOI=10.1002/gcc.20717;
RA   Ottaviano L., Schaefer K.-L., Gajewski M., Huckenbeck W., Baldus S.,
RA   Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H.,
RA   Meza-Zepeda L.A., Serra M., Cleton-Jansen A.-M., Hogendoorn P.C.W.,
RA   Buerger H., Aigner T., Gabbert H.E., Poremba C.;
RT   "Molecular characterization of commonly used cell lines for bone tumor
RT   research: a trans-European EuroBoNet effort.";
RL   Genes Chromosomes Cancer 49:40-51(2010).
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
RX   PubMed=21519327; DOI=10.1038/labinvest.2011.72;
RA   Mohseny A.B., Machado I., Cai Y., Schaefer K.-L., Serra M.,
RA   Hogendoorn P.C.W., Llombart-Bosch A., Cleton-Jansen A.-M.;
RT   "Functional characterization of osteosarcoma cell lines provides
RT   representative models to study the human disease.";
RL   Lab. Invest. 91:1195-1205(2011).
RX   PubMed=22075555; DOI=10.1158/0008-5472.CAN-11-2778;
RA   Huang G., Yu L., Cooper L.J., Hollomon M., Huls H., Kleinerman E.S.;
RT   "Genetically modified T cells targeting interleukin-11 receptor
RT   alpha-chain kill human osteosarcoma cells and induce the regression of
RT   established osteosarcoma lung metastases.";
RL   Cancer Res. 72:271-281(2012).
RX   PubMed=23671654; DOI=10.1371/journal.pone.0063056;
RA   Lu Y.-H., Soong T.D., Elemento O.;
RT   "A novel approach for characterizing microsatellite instability in
RT   cancer cells.";
RL   PLoS ONE 8:E63056-E63056(2013).
RX   PubMed=24758355; DOI=10.1186/1471-2407-14-281;
RA   Moneo V., Serelde B.G., Blanco-Aparicio C., Diaz-Uriarte R.,
RA   Aviles P., Santamaria G., Tercero J.C., Cuevas C., Carnero A.;
RT   "Levels of active tyrosine kinase receptor determine the tumor
RT   response to Zalypsis.";
RL   BMC Cancer 14:281.1-281.10(2014).
RX   PubMed=25031706;
RA   Du L., Fan Q.-M., Tu B., Yan W., Tang T.-T.;
RT   "Establishment and characterization of a new highly metastatic human
RT   osteosarcoma cell line derived from Saos2.";
RL   Int. J. Clin. Exp. Pathol. 7:2871-2882(2014).
RX   PubMed=26320182; DOI=10.18632/oncotarget.5177;
RA   Ren L., Mendoza A., Zhu J., Briggs J.W., Halsey C., Hong E.S.,
RA   Burkett S.S., Morrow J.J., Lizardo M.M., Osborne T., Li S.Q.,
RA   Luu H.-H., Meltzer P.S., Khanna C.;
RT   "Characterization of the metastatic phenotype of a panel of
RT   established osteosarcoma cells.";
RL   Oncotarget 6:29469-29481(2015).
RX   PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074;
RA   Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E.,
RA   Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J.,
RA   Harris E., Monks A., Morris J.;
RT   "Sarcoma cell line screen of oncology drugs and investigational agents
RT   identifies patterns associated with gene and microRNA expression.";
RL   Mol. Cancer Ther. 14:2452-2462(2015).
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
RX   PubMed=29334376; DOI=10.1038/nm.4475;
RA   Morrow J.J., Bayles I., Funnell A.P.W., Miller T.E., Saiakhova A.,
RA   Lizardo M.M., Bartels C.F., Kapteijn M.Y., Hung S., Mendoza A.,
RA   Dhillon G., Chee D.R., Myers J.T., Allen F., Gambarotti M., Righi A.,
RA   DiFeo A., Rubin B.P., Huang A.Y., Meltzer P.S., Helman L.J., Picci P.,
RA   Versteeg H.H., Stamatoyannopoulos J.A., Khanna C., Scacheri P.C.;
RT   "Positively selected enhancer elements endow osteosarcoma cells with
RT   metastatic competence.";
RL   Nat. Med. 24:176-185(2018).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).